Ironwood Pharmaceuticals, Inc.
Simbols: IRWD
NASDAQ
6.74
USDTirgus cena šodien
-1.0492
P/E koeficients
0.1032
PEG koeficients
1.07B
MRK Cap
- 0.00%
DIV ienesīgums
Ironwood Pharmaceuticals, Inc. (IRWD) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 92.2 | 656.2 | 620.1 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 0 | 129.1 | 115.5 | 114 | |||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 1.3 | 1.3 | |||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 12 | 7.7 | 9.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 233.3 | 780.6 | 745.2 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 18.2 | 20.3 | 22.9 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 3.7 | 0 | 0 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 3.7 | -15.1 | -24.5 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 15.1 | 24.5 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 212.3 | 283.7 | 333.3 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 3.6 | 15.9 | 25.5 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 237.8 | 319.9 | 381.7 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 0 | 471.1 | 1100.5 | 1126.9 | |||||||||||||||||
balance-sheet.row.account-payables | 0 | 7.8 | 0.5 | 0.9 | |||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 202.7 | 3.1 | 120 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 1.2 | 0.7 | 0.2 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 498.3 | 412.9 | 355.8 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 64.3 | 22 | 1.3 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 541.3 | 422.6 | 359.3 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 14.5 | 19.7 | 21.6 | |||||||||||||||||
balance-sheet.row.total-liab | 0 | 817.4 | 448.1 | 521 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 0.2 | 0.2 | 0.2 | |||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -1698.6 | -696.4 | -937.6 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -3 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1355.2 | 1348.6 | 1543.4 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -346.3 | 652.4 | 605.9 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 471.1 | 1100.5 | 1126.9 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | 0 | -346.3 | 652.4 | 605.9 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||
Total Investments | 0 | 0 | 15.1 | 24.5 | |||||||||||||||||
balance-sheet.row.total-debt | 0 | 715.5 | 415.9 | 475.8 | |||||||||||||||||
balance-sheet.row.net-debt | 0 | 623.4 | -240.3 | -144.3 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -1002.2 | 175.1 | 528.4 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 1.6 | 1.4 | 1.5 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 72.6 | 65.7 | -333.3 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 32 | 27 | 22.3 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 11.3 | 2.8 | 17.7 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 0.9 | 8 | 7.7 | |||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 12.4 | -8.1 | -2.6 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -2 | 2.9 | 12.7 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 1068.2 | 1.7 | 25.2 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -0.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -1026 | 0 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -1026.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -300 | -120.7 | 0 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 6.4 | 9.5 | 19.6 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -126.4 | -24.1 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -111.2 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 570.8 | 111.2 | -4.5 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 277.2 | -237.6 | -4.5 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -565.3 | 36.1 | 257.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 92.2 | 657.9 | 621.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 657.5 | 621.9 | 364.8 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 183.4 | 273.8 | 261.9 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -0.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 183.2 | 273.6 | 261.6 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 442.7 | 410.6 | 413.8 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 1.6 | 1.4 | 1.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 0 | 441.2 | 409.2 | 412.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 232.1 | 160.3 | 181.5 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 233.7 | 160.3 | 181.5 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 19 | 9.5 | 0.7 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 21.6 | 7.6 | 31.1 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -1157.1 | 2.1 | -31.6 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -1157.1 | 2.1 | -31.6 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 21.6 | 7.6 | 31.1 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1.6 | 9.5 | 0.7 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 0 | 209 | 250.3 | 232.3 | |||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -948.1 | 252.4 | 200.7 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 83.5 | 77.4 | -327.8 | |||||||||||||||||
income-statement-row.row.net-income | 0 | -1002.2 | 175.1 | 528.4 |
Biežāk uzdotie jautājumi
Kas ir Ironwood Pharmaceuticals, Inc. (IRWD) kopējie aktīvi?
Ironwood Pharmaceuticals, Inc. (IRWD) kopējie aktīvi ir 471073000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.996.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 1.174.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -2.264.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -2.120.
Kāda ir Ironwood Pharmaceuticals, Inc. (IRWD) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -1002239000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 715538000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 232124000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.